Identification and characterization of the factor Va binding site on prothrombin.

在血管损伤时，凝血系统被激活以停止失血并开始伤口愈合和损伤修复的过程。凝血系统由依次激活下游酶复合物的酶复合物组成。一个共同的特征是这些复合物都含有1）酶，2）辅因子，3）钙，和4）带负电荷的细胞表面。在所有情况下，即使酶能够单独作用于底物，但其辅因子的存在使反应增强103至105倍。因此，了解这些辅助因子发挥作用的平行机制对于我们理解凝血系统和潜在的治疗方案至关重要。在这些复合物中，当其前体凝血酶原（PT）被凝血酶原酶复合物（凝血酶原酶复合物）激活时，产生中心凝血酶凝血酶。酶由酶因子（F）Xa、辅因子FVa、钙和细胞表面组成。虽然PT可以被单独的FXa激活，但是当FXa处于非激活状态时，该反应增强了300，000倍。尽管这些相互作用的重要性，以及这个主题背后数十年的研究工作，FVa如何发挥其辅因子功能的确切机制仍然难以捉摸。这部分是由于PT激活的潜在机制的复杂性。此外，FVa如何结合PT并呈递给FXa仍然没有答案。这是特别重要的，因为FV（a）相对于FXa的丰度决定了PT-FVa相互作用在将PT呈递给FXa中可能是至关重要的。因此，我们希望研究负责与FVa相互作用的PT区域，并因此允许FVa在PT被IFN活化期间发挥其辅因子活性。我们有初步数据表明PT的kringle 2结构域的外表面参与FVa重链的结合。更具体地，我们已经使用NMR鉴定了PT上直接结合FVa的六个残基。然后，我们产生了PT变体，其中这六个残基被惰性残基取代。该PT变体的激活导致主要中间体的形成大幅减少以及凝血酶生成显著减少，表明PT激活机制发生了重大变化。在这个提议中，我们的目标是通过直接表征FVa-PT相互作用来进一步研究我们的初步发现。此外，我们还将使用新鲜获得的活化血小板来代替通常用于模拟磷酸酶组装的活化细胞表面的带负电荷的合成脂质囊泡。*因此，我们的研究将产生的潜在影响是更好地了解这些非酶蛋白辅助因子如何促进血凝块形成。通过回答这些长期存在的问题，我们的目标是在理解调节凝血的生化过程方面开辟令人兴奋的新天地。

Upon vascular injury, the coagulation system is activated in order to stop the blood loss and begin the process of wound healing and damage repair. The clotting system consists of enzyme complexes that sequentially activate downstream enzyme complexes. One characteristic in common is that these complexes all contain 1) enzyme, 2) cofactor, 3) calcium, and 4) negatively charged cell surface. In all instances, even though the enzyme is able to act on the substrate alone, the presence of its cofactor enhances the reaction by 103- to 105-fold. Therefore, understanding the parallel mechanism by which these cofactors exert their effect is critical in our understanding of the coagulation system and potentially developing treatment options.***Of these complexes, the central clotting enzyme thrombin is generated when its precursor prothrombin (PT) is activated by the prothrombinase complex (Pase). Pase consists of the enzyme factor (F) Xa, cofactor FVa, calcium and cell surface. While PT can be activated by FXa alone, this reaction is enhanced by 300,000-fold when FXa is in Pase. Despite the importance of these interactions, and decades of research work behind this topic, the exact mechanism of how FVa exerts its cofactor function remains elusive. This is partly due to the complexity in the underlying mechanism of PT activation by Pase. Furthermore, how FVa binds PT and is presented to FXa remains unanswered. This is particularly of importance since the abundance of FV(a) relative to FXa dictates that PT-FVa interaction may be crucial in presenting PT to FXa. Therefore, we wish to investigate the region of PT that is responsible for interacting with FVa, and thus allowing FVa to exert its cofactor activity during PT activation by Pase.***We have preliminary data that demonstrate that the outer face of kringle 2 domain of PT is involved in binding the heavy chain of FVa. More specifically, we have identified six residues on PT that directly bind FVa using NMR. We then generated a PT variant with these six residues substituted with inert residues. Activation of this PT variant led to a substantial decrease in the formation of a major intermediate as well as a significant decrease in thrombin generation, suggesting that there has been a major change in the mechanism of PT activation. In this proposal, we aim to further investigate our initial findings by directly characterizing the FVa-PT interaction. Furthermore, in place of the negatively charged synthetic lipid vesicles that are typically used to mimic the activated cell surface to which Pase is assembled, we will also use activated platelets that are obtained fresh.***Therefore, the potential impact our research will have is a better understanding of how these non-enzymatic protein cofactors work to enhance blood clot formation. By answering these long standing questions, we aim to break exciting new ground in understanding the biochemical processes that modulate coagulation.**